W hile heart failure with reduced ejection fraction (HFREF) and heart failure with preserved ejection fraction (HFPEF) share many symptomatic and clinical features, HFPEF has emerged over the past decade as a particularly challenging disorder to treat. For patients with HFREF, pharmacologic intervention with angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, mineralocortcoid antagonists, and b-adrenoceptor blockers have clearly been shown to improve symptoms, ventricular performance, and prognosis. In contrast, HFPEF, a disorder characterized by normal or nearly normal left ventricular (LV) systolic function and evidence of diastolic dysfunction, 1,2 has yet to be convincingly affected by any of these therapies and other, more recently investigated agents including phosphodiesterase type 5 inhibitors. 3, 4 Patients with HFPEF are typically older than patients with HFREF and have a higher incidence of underlying diseases such as hypertension, diabetes, and atrial fibrillation.
3 HFPEF currently accounts for approximately half of all hospital admissions for heart failure, 5 and given that the average population age is increasing, it is likely that hospitalizations due to HFPEF will increase in the near term. Taken together, given the lack of therapeutic options for HFPEF, there is a major need to better understand the pathogenesis of HFPEF to be able to develop more effective therapies.
The lack of effective therapies for HFPEF suggests that current interventions may not effectively target key contributory mechanisms or that they are unable to sufficiently modify their targets. For HFPEF patients, exertional dyspnea and corresponding exercise intolerance are the key symptoms [6] [7] [8] ; this has been ascribed to impaired diastolic reserve. 9, 10 The specific mechanism responsible for the impairment of diastolic reserve, remains a source of considerable conjecture. While the passive effects of interstitial fibrosis are commonly proposed to underlie the abnormal diastology in HFPEF, it is also possible that impaired active relaxation of the heart plays a contributory role. 11, 12 In the present study, we considered the possibility that the impairment in diastolic reserve, particularly in the context of exertion, may reflect abnormalities of the active relaxation phase of diastole and, further, that this is a process initiated by underlying factors such as hypertension. We therefore investigated the relationship between resting and exercise hemodynamics and measures of myocardial oxygen delivery in healthy control volunteers, hypertensive subjects, and patients with HFPEF.
Methods

Patient Population
Healthy volunteers were recruited from the general community and had no history of significant comorbidities including cardiovascular, pulmonary, or other systemic diseases. Hypertensive controls were included if they had a reported blood pressure >140/90 mm Hg, were treated with antihypertensive medication, and were free from a history of limiting exertional dyspnea. HFPEF patients were recruited from the Alfred Hospital Heart Centre clinics or at the time of evaluation for suspected HFPEF. HFPEF patients were included on the basis of a history of exertional dyspnea, LV ejection fraction >45%, and either resting echocardiographic features of definite diastolic dysfunction (E/e 0 >15) or an exercise pulmonary capillary wedge pressure (PCWP) >25 mm Hg as suggested by us 13 and others. Patients were excluded if they had a body mass index (BMI) >35 kg/m 2 , unstable coronary artery disease, or history of stress-induced syncope or ventricular tachycardia during exercise or were unable to perform an exercise test. The study was approved by the Alfred Hospital Research and Ethics Committee, and all participants provided written informed consent.
Cardiac Catheterization
A 7Fr balloon-tipped pulmonary artery catheter (Edwards Lifesciences) was inserted through an introducer sheath placed in the right internal jugular or a brachial vein for measurement of right atrial pressure, pulmonary artery pressure, and PCWP. The wedge position was confirmed by the use of fluoroscopy and pressure waveform, and the mean PCWP was measured at end-expiration. Cardiac output was measured by using thermodilution with measurements taken in triplicate or from 5 readings for patients in atrial fibrillation. A 3Fr radial or brachial artery cannula was inserted for blood pressure recording and blood sampling. A second catheter, inserted through an introducer sheath in a brachial vein, was placed in the coronary sinus for blood sampling. After baseline hemodynamic measurements, simultaneous arterial and coronary sinus blood samples were obtained for measurement of blood gases, glucose, and lactate. Subjects then exercised in the supine position on a cycle ergometer mounted onto the catheter table. Subjects started at a work rate of 0.3 W/kg body weight for 3 minutes. The workload was increased to 0.6, 1.0, and 1.5 W/kg, respectively, every 3 minutes or to maximum tolerated levels, as we previously described. 8 Hemodynamic indices were obtained again at peak exercise, and when a stable coronary sinus catheter position was maintained, repeat arterial and coronary sinus blood gas samples were obtained. 
Results
Baseline Characteristics
The present study included HFPEF patients, hypertensive patients, and healthy control subjects. As demonstrated in Table 1 , HFPEF patients were older and hypertensive and more likely to be receiving antihypertensive and heart failure medication.
Cardiac Structure and Function
As illustrated in Table 1 , LV ejection fraction (LVEF) was similar for all 3 groups. HFPEF patients were characterized by echocardiographic features of LV hypertrophy compared with controls, and there was a concomitant, significant increase in left atrial volume index compared with healthy subjects. The hypertensive subjects were asymptomatic and were well treated for hypertension.
Resting and Exercise Hemodynamics and Echocardiography
At rest, mean arterial blood pressure was similar across the 3 study groups; systolic blood pressure was higher in HFPEF patients compared with controls (153AE4 versus 130AE4 mm Hg, P<0.01), whereas hypertensive subjects had an average systolic blood pressure of 143AE6 mm Hg. Consistent with their diagnosis, the mean pulmonary artery and mean PCWP at rest were significantly higher in HFPEF patients (Table 2 ), while cardiac index was similar across the 3 groups. During a symptom-limited exercise hemodynamic study, patients with HFPEF displayed a significantly diminished peak exercise capacity compared with healthy controls (43AE8 versus 114 AE12 W, P<0.001). Exercise capacity in hypertensive subjects (87AE14 W) was greater than that in HFPEF (P<0.05), and although it was lower than that of controls, the difference was not statistically significant. As shown in Table 2 , the exercise time was also significantly shorter in HFPEF patients. During exercise, all groups significantly increased cardiac output (control and hypertensive subjects both P<0.001; HFPEF subjects, P<0.01); however, the peak cardiac index was significantly lower in HFPEF subjects (Table 2) . Consistent with these data, HFPEF patients displayed a decreased peak exercise LVEF (59AE3%) compared with hypertensive subjects (74AE2%, P=0.003) and healthy controls (74AE2%, P<0.001). As shown in Figure 1 , the LV endsystolic and end-systolic volume indexes were significantly smaller in the HFPEF group at baseline. During exercise, there was a significant fall in the LV end-systolic volume index in both control and hypertensive subjects in contrast to that observed in HFPEF subjects. The heart rate responses to exertion were similar across groups, while the stroke volume response to exercise was significantly lower in HFPEF patients (P<0.05) compared with healthy subjects. As expected exercise resulted in significant within-group increases in heart rate, systemic and pulmonary pressures, and cardiac index ( Table 2) . Consistent with prior studies, the PCWP at peak exercise in HFPEF patients was markedly higher than that in controls or hypertensives (both P<0.001, Table 3 ). Furthermore, after accounting for baseline differences in resting PCWP, the magnitude of the rise in PCWP during exercise continued to be greater in HFPEF compared with either control or hypertensive subjects (both P<0.05). The peak cardiac index and LV work were significantly lower in HFPEF patients (Table 3) . Double product was higher in HFPEF patients at rest compared with controls but did not differ during exercise as shown in Table 3 .
Given that exercise capacity in HFPEF was limited due to symptoms, we explored the relationship between workload and hemodynamic performance. Peak LV work was significantly correlated with peak workload (r=0.46, P=0.01). The peak PCWP normalized to work was significantly higher in HFPEF patients compared with control or hypertensive subjects (HFPEF 76AE12 mm Hg/W per kg versus control 11AE1 mmHg/W per kg and hypertension 15AE1 mm Hg/W per kg, both P<0.001).
Rest and Exercise Arterial and Coronary Sinus Oxygen Content
Complete transcardiac blood sampling data were obtained in 10 controls, 7 hypertensives, and 8 HFPEF patients. In Figure 2A , as was the transcardiac release gradient for the carbon dioxide content (CcsCO 2 -CaCO 2 ) for controls, hypertensives, and HFPEF patients:
11.1AE0.8, 9.8AE0.8, and 8.1AE1.0 mLCO 2 /100 mL. During exercise, there was a significant within-group increase in the transcardiac gradient for oxygen in all groups; however, the magnitude was smaller in HFPEF patients. Control subjects (rest versus exercise: 112AE3 versus 149AE4 mL O 2 /100 mL, P<0.001), hypertensives (rest versus exercise: 120AE4 versus 136AE5 mL O 2 /100 mL, P<0.001), and HFPEF (rest versus exercise: 112AE7 versus 125AE6 mL O 2 /100 mL, P=0.01).
The peak transcardiac oxygen gradient was significantly less in HFPEF patients as shown in Figure 2B . When comparing the capacity for enhanced myocardial extraction of oxygen during exercise, the increase in the transcardiac oxygen gradient during exercise was significantly blunted in both hypertensives and HFPEF patients ( Figure 2C ). Furthermore, on ANCOVA, the between-group differences in exercise stimulated transcardiac oxygen gradient were not explained by differences in either age (P=0.76) or workload (P=0.43). We next determined whether the capacity for augmented myocardial oxygen extraction during exercise was associated with the exercise-induced change in PCWP. As shown in Figure 3 , there was a significant negative correlation between the change in the transcardiac oxygen gradient and the exercise-induced peak PCWP, suggesting that limitation of oxygen extraction capacity could be associated with elevated exercise PCWP. Across the entire cohort, there was a significant correlation between LV work and the transcardiac oxygen gradient (r=0.55, P<0.001). Therefore, to exclude the possibility that the reduction in transcardiac oxygen gradient in HFPEF and hypertensive patients was due to lower LV work, we performed an ANCOVA. In this analysis, the transcardiac oxygen gradient remained significantly lower in HFPEF patients compared with that in control subjects (P<0.001).
In an attempt to ascertain whether there was evidence of a change in myocardial substrate metabolism during the progressive stage of hypertension to HFPEF, we measured the transcardiac gradients for glucose and lactate at rest and exercise in the 3 study cohorts. At rest and during exercise, significant transcardiac extraction of glucose occurred across the entire cohort (rest, arterial vs coronary sinus: 5.88AE0.14 versus 5.57AE0.12 mmol/L P=0.001; exercise, arterial vs coronary sinus: 5.93AE0.13 versus 5.56AE0.08 mmol/L P<0.001). However, there was no significant difference between groups, and exercise did not significantly alter the transcardiac gradient. As shown in Figure 4 , net transcardiac uptake gradients were also evident for lactate. Exercise increased the uptake of lactate significantly across all groups, with no significant difference in the magnitude of uptake between the groups.
Discussion
In contrast to HFREF, there has been limited progress in regard to the development of effective therapies that improve functional capacity and outcome for patients with HFPEF. To some extent, this impasse may represent the complex pathophysiology of HFPEF and the fact that the predisposing risk factors, such as hypertension, appear to be more prevalent in HFPEF than in HFREF. 3 Accumulating data suggest that HFPEF is a syndrome that reflects contributions from several mechanisms, including myocardial, vascular, and noncardiovascular elements. In particular, altered diastolic reserve is the key mechanism, together with increased vascular stiffness, reduced endothelial function, abnormal ventriculovascular coupling, and pulmonary vascular remodeling. In the present study, we showed that HFPEF patients exhibited a rapid rise in PCWP at low workload consistent with altered diastolic reserve as previously reported. 8 Our study also examined the hemodynamic response in a group of subjects with well-controlled hypertension, without significant LV hypertrophy. This subject group demonstrated a similar change in PCWP during exercise, albeit at a somewhat lower tolerated workload. In the setting of symptomatic limitation, HFPEF patients were unable to achieve workloads of a similar magnitude to that in control and hypertensive subjects. Recent clinical trials of angiotensin-converting enzyme inhibition, angiotensin II receptor blockade, and aldosterone antagonism [18] [19] [20] have, in part, been predicated on the assumption that the increase in ventricular stiffness due to extracellular matrix accumulation is a key determinant of the pathophysiology and outcome of HFPEF. 21 The lack of effective outcomes with these interventions raises the possibility that the interventions do not sufficiently reverse cardiac fibrosis or, alternatively, that they do not target the appropriate mechanism underpinning altered diastology. As such, the precise role of interstitial fibrosis alone, however, is somewhat unclear. For example, a recent study of volume loading in HFPEF patients showed a similar magnitude of increase in LV filling pressures to that observed in healthy controls, suggesting passive diastolic stiffness may be less important. 22 Diastolic performance is determined by both active energy requiring and passive components that contribute to the rate of relaxation and the stiffness of the ventricle. We found that patients with HFPEF had smaller baseline LV end-systolic and end-systolic volume indexes, as previously observed. 23 During exercise, the LV end-systolic volume index did not change significantly in any group consistent with previous studies 24 ; however, the LV end-systolic volume index fell significantly in control and hypertensive subjects consistent with preserved contractile reserve. The relationship between apparently reduced contractile reserve and the inability of the left ventricle to relax rapidly and to a sufficient extent to maintain a low filling pressure may be explained in several ways. As reviewed in detail by Tschope and Paulus, 25 diastolic lengthening velocity is influenced by systolic shortening, reflecting the contribution of restorative forces mediated by the bidirectional "spring" protein, titin. In the present study, we found that contractile reserve was reduced, albeit at a lower workload due to symptom limitation, thus possibly contributing to impaired diastolic reserve. Moreover, in the context of HFPEF it has been proposed that a switch to the less-compliant N2BA isoform of titin and the relative hypophosphorylation are responsible.
Beyond the potential contribution of altered structural protein expression and function, we considered the possibility that abnormalities of myocardial energetics might also contribute to the physiological defect that characterize HFPEF. In particular, given that coronary flow reserve has been previously shown to be impaired in hypertensives, 26, 27 we aimed to test the hypothesis that impaired myocardial oxygen delivery might be an important contributor to impaired exercise diastolic reserve in HFPEF via its influence of diastolic performance. We performed simultaneous hemodynamic studies and transcardiac blood sampling at rest and during exercise and compared these observations with those in healthy control subjects and asymptomatic hypertensive individuals. In each group, during exercise there was a significant increase in the transcardiac oxygen gradient, consistent with increased extraction of oxygen by the myocardium. Importantly, we found that the LV-work corrected transcardiac oxygen gradient was significantly lower in HFPEF patients compared with controls. Moreover, we observed that the coronary sinus oxygen content was lowest in individuals with the highest peak PCWP during exercise. Under normal circumstances, myocardial oxygen consumption occurring during increased cardiac work is achieved by an increase in myocardial blood flow together with an increase in myocardial oxygen extraction. 28 As such, the present data are highly suggestive of an impairment of myocardial oxygen delivery due to microvascular dysfunction, and such an abnormality could potentially contribute to the exercise induced diastolic dysfunction observed in HFPEF. The notion of impaired oxygen delivery is consistent with recent studies in skeletal muscle demonstrating reduced capillary density. 29 In the present study, we were not able to calculate total myocardial oxygen consumption, given that the simultaneous measurement of myocardial blood flow during coronary venous blood sampling with exercise is not presently possible due to the lack of clinically approved coronary sinus thermodilution catheters. From a mechanistic perspective, impaired myocardial blood flow reserve during exertion could be explained by several potential mechanisms. The increment in blood flow that accompanies increased ventricular work is currently thought to reflect the actions of locally generated metabolites such as adenosine, together with shear stress-induced release of nitric oxide by the endothelium. 30 In this context, we and others have shown that the systemic and local vascular responses to exercise and metabolic stress are reduced in HFPEF patients, consistent with endothelial dysfunction. 8, 24 Alternatively, impaired vasodilator capacity may also reflect a reduction in the absolute cross-sectional area (ie, number of resistance vessels) of the microcirculation, given that this limitation to flow may only become evident at maximal vasodilatation. 30, 31 Consistent with this possibility, recent studies in myocardial biopsy samples from patients undergoing cardiac surgery showed reduced microvascular density in obesity, 32 the latter being associated with HFPEF.
Our studies, therefore, suggest that myocardial oxygen delivery may be limiting in HFPEF patients. Myocardial oxygen is closely coupled with ATP production and external work, 33 although previous studies indicate that in healthy subjects, only 25% of the oxygen consumed ultimately participates in external work. 34 Phan and colleagues 35 demonstrated the presence of a reduced phosphocreatine-to-ATP ratio in HFPEF patients consistent with the possibility that myocardial oxygen availability may be limiting in HFPEF. In particular, ATP is required during diastole for the detachment of the myosin head from actin and for the removal of Ca 2+ from the contractile apparatus back to the sarcoplasmic reticulum. It is also possible that Ca 2+ leak from the sarcoplasmic reticulum leading to elevated diastolic Ca 2+ levels may lead to increased ATP use together with incomplete diastolic relaxation due to active resting tone. 36 This process was also demonstrated to be more apparent at higher heart rates, including the range observed during exercise in the current study. However, previous studies using rapid pacing suggest that elevated heart rate in the absence of a change in afterload may not be sufficient to induce diastolic dysfunction. 37 In addition to our new findings in relation to the myocardial biology of HFPEF, it is evident that the clinical features of HFPEF represent the integrated effects of multisystem alterations. These include impaired endothelial function, impaired skeletal muscle oxygen delivery, ventriculovascular mismatch, elevated arterial stiffness, renal impairment, pulmonary dysfunction, and obesity among others.
Our study has several limitations. By its invasive nature, the sample size was small; however, clear between-group differences were evident. It is also possible that smaller between-group differences may not have been detected. There were some differences in the demographic features of the control and HFPEF groups, notably in regard to age and BMI. In a recent study of healthy subjects, we demonstrated that although a higher PCWP and lower cardiac output during exercise are associated with aging, the magnitude of the influence of age is far less than that observed in HFPEF, indicating that age per se was not a major confounding factor in the present study. 38 In addition, on ANCOVA, we found that age was not a significant contributor to the observed between-group differences in key hemodynamic variables such as the exercise-induced PCWP. The hypertensive group and HFPEF patients had a higher BMI than controls, but the hemodynamic responses in hypertensives were similar to that in controls, indicating that BMI per se was not responsible for the findings in our study. Accordingly, we believe the relevance of between-group differences in age and BMI in our study to be limited. Taken together, the present study suggests that patients with HFPEF may have an intrinsic inability to increase myocardial oxygen delivery during exertion due to microvascular dysfunction, which would contribute to defective active relaxation, particularly during physical activity. The application of noninvasive methodology including cardiac magnetic resonance imaging-and positron emission tomographybased assessment of myocardial metabolism during exertion in larger numbers of HFPEF patients may also yield insights into the frequency and extent of microvascular abnormalities in this difficult-to-treat patient group, which may lead to the evaluation of targeted therapeutic modalities.
